2-[2-[6-(3,5-Dimethyl-1,2,4-triazol-1-yl)-2-methylpyrimidin-4-yl]cyclopropyl]-6-methylimidazo[1,2-a]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-[2-[6-(3,5-Dimethyl-1,2,4-triazol-1-yl)-2-methylpyrimidin-4-yl]cyclopropyl]-6-methylimidazo[1,2-a]pyridine
• 英文别名: 2-[2-[6-(3,5-dimethyl-1,2,4-triazol-1-yl)-2-methylpyrimidin-4-yl]cyclopropyl]-6-methylimidazo[1,2-a]pyridine
• 化学式: C₂₀H₂₁N₇
• 分子量: 359.4
• InChiKey: REGAKVSVLXHWIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  73.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] CYCLOPROPYL IMIDAZOPYRIDINE PDE10 INHIBITORS<br/>[FR] CYCLOPROPYLIMIDAZOPYRIDINE UTILISABLE EN TANT QU'INHIBITEUR DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2014078217A1

  公开（公告）日：2014-05-22

  The present invention is directed to substituted cyclopropyl imidazopyridine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统紊乱的治疗剂的取代环丙基咪唑吡啶化合物。本发明还涉及利用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的疾病。
• CYCLOPROPYL IMIDAZOPYRIDINE PDE10 INHIBITORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20150307488A1

  公开（公告）日：2015-10-29

  The present invention is directed to substituted cyclopropyl imidazopyridine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及替代环丙基咪唑吡啶化合物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经和精神障碍，例如精神分裂症、精神病或亨廷顿病，以及与纹状体低功能或基底节功能障碍有关的疾病。
• US9359348B2
  申请人：——

  公开号：US9359348B2

  公开（公告）日：2016-06-07